ASCO: Nivolumab, Relatlimab Combo Slows Advanced Melanoma

Median progression - free survival of 10.1 versus 4.6 months seen among those receiving combo versus nivolumab alone, respectively
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news